FTC crashes tea party
This article was originally published in The Tan Sheet
Executive Summary
The Federal Trade Commission orders $31.7 million judgement against health care companies for marketing an herbal tea with unsubstantiated claims and deceptively selling health care business opportunities. The defendants claimed an herbal tea they sold could prevent, treat or cure diseases including AIDS, diabetes, cancer and arthritis, FTC says. The defendants - Jeffrey W. McLain, his sons Alexander McLain and Victor McLain, and the firms Prophet 3H, Georgia Home Health Care License and Certification Institute, Healthcare State License and Certification Institute, and M7 Holdings - also conducted conferences to sell "bogus healthcare business ventures," FTC says Dec. 21...
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.